The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.

نویسندگان

  • Joanna B Madalinska
  • Marc van Beurden
  • Eveline M A Bleiker
  • Heiddis B Valdimarsdottir
  • Judith Hollenstein
  • Leon F Massuger
  • Katja N Gaarenstroom
  • Marian J E Mourits
  • René H M Verheijen
  • Eleonora B L van Dorst
  • Hans van der Putten
  • Ko van der Velden
  • Henk Boonstra
  • Neil K Aaronson
چکیده

PURPOSE Preventive health strategies for women at increased hereditary risk of ovarian cancer include gynecologic screening (GS) and/or prophylactic oophorectomy (PBSO). Hormone replacement therapy (HRT) is often prescribed to compensate for postsurgical endocrine deficiencies. This study examined the impact of HRT use on levels of endocrine symptoms and sexual functioning among premenopausal women who have undergone PBSO. Comparisons were made with similar women undergoing GS. PATIENTS AND METHODS Questionnaire data on endocrine symptoms and sexual functioning were obtained from 450 premenopausal, high-risk women who had participated in this nationwide, cross-sectional, observational study. RESULTS Thirty-six percent of women had undergone PBSO and 64% had opted for GS. In the PBSO group, 47% of the women were current HRT users. They reported significantly fewer vasomotor symptoms than nonusers (P < .05). However, compared with premenopausal women undergoing GS, oophorectomized HRT users were more likely to report vasomotor symptoms (P < .01). HRT users and nonusers reported comparable levels of sexual functioning. Compared with women in the GS group, oophorectomized HRT users reported significantly more sexual discomfort due to vaginal dryness and dyspareunia (P < .01). CONCLUSION Although HRT has a positive impact on surgically induced vasomotor symptoms, it may be less effective than is often assumed. Symptom levels remain well above those of premenopausal women undergoing screening, and sexual discomfort is not alleviated by HRT. Physicians need to provide younger high-risk women considering PBSO with realistic information about both benefits and drawbacks of this preventive strategy, including information about premature menopause and HRT.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Hormone replacement therapy for a young woman with cervical sarcomatoid squamous cell carcinoma

Cervical sarcomatoid squamous cell carcinoma (SSCC) is an extremely rare malignancy. We report the case of a young woman with cervical SSCC who experienced peri-menopausal syndrome following treatment, and present our evaluation of the considerations relating to hormone replacement therapy (HRT) in this case. A 24-yearold Chinese woman with SSCC underwent radical hysterectomy with bilateral sal...

متن کامل

What Happens After Menopause? (WHAM): protocol for a prospective, multicentre, age-matched cohort trial of risk-reducing bilateral salpingo-oophorectomy in high-risk premenopausal women

INTRODUCTION Women at high inherited risk of ovarian cancer are advised to undergo risk-reducing bilateral salpingo-oophorectomy (RRBSO) at age 40-45 years or when their families are complete. Most women are premenopausal at this age, so RRBSO will induce surgical menopause. Despite the clear benefits of RRBSO for cancer risk reduction, much less is known about the impact on non-cancer outcomes...

متن کامل

Women's use of hormone replacement therapy for relief of menopausal symptoms, for prevention of osteoporosis, and after hysterectomy.

BACKGROUND Hormone replacement therapy is used for the relief of menopausal symptoms. In the United Kingdom, guidelines have been developed for the use of hormone replacement therapy in the prevention of osteoporosis, and in the United States of America its use has also been recommended for cardiovascular disease prevention. However, compliance has been found to be a problem, and rates of presc...

متن کامل

Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.

Germline mutations in BRCA1 or BRCA2 genes redispose to hereditary breast and ovarian cancers. he estimated lifetime risk of breast cancer in BRCA1 utation carriers ranges from 50% to 80%, while the stimated lifetime risk of ovarian cancer ranges from 0% to 65%. Although breast cancer risk is similar in omen who inherit BRCA2 mutations, the lifetime risk f ovarian cancer is approximately 20% [1...

متن کامل

Attitude and knowledge of women about menopause and hormone replacement therapy

Abstract: Introduction: Menopause is one of four crises of women&rsquo;s life that predispose for many of hormonal change. Menopause is the stage of women&rsquo;s life in which ovarian function is terminated and level of estrone hormones that are secreted form ovarianes, severely reduced. Menopause accompanied with remarkable somatic and psychologic changes. The most important of these changes ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology

دوره 24 22  شماره 

صفحات  -

تاریخ انتشار 2006